@article{ref1,
title="Diagnosis and management of erectile dysfunction in the primary care setting",
journal="International journal of clinical practice",
year="2007",
author="Rosenberg, M. T.",
volume="61",
number="7",
pages="1198-1208",
abstract="Recent advances in the management of erectile dysfunction (ED) involve the use of oral phosphodiesterase type-5 (PDE-5) inhibitor therapies which have transformed the perception of ED for both the patient and the healthcare provider. Recent treatment guidelines, including the American Urological Association (AUA) 2005 guidelines, promote a goal-oriented approach to therapy and emphasise that PDE-5 therapy should be offered to patients with ED as a first-line treatment option, unless contraindicated. Evidence-based studies have identified an association between ED and the presence of risk factors for cardiovascular and other vascular diseases, implicating ED as a marker for other vascular conditions. Therefore, the importance of screening and diagnosis in the primary care setting is paramount in the diagnosis and management of ED-associated comorbidities. This review provides an update on ED screening and management focusing on the use of PDE-5 inhibitor therapy in the primary care setting and also discusses clinical efficacy parameters with regard to recent results from clinical trials.<p />",
language="",
issn="1368-5031",
doi="10.1111/j.1742-1241.2007.01418.x",
url="http://dx.doi.org/10.1111/j.1742-1241.2007.01418.x"
}